Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054682 | 0.87 | DDAH1 (0.49) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5623032 | 0.81 | DDAH1 (0.65) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL10936024 | 0.80 | DDAH1 (0.55) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL10936030 | 0.80 | DDAH1 (0.55) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL8409996 | 0.78 | DDAH1 (0.71) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4188069 | 0.78 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL774784 | 0.77 | DDAH1 (0.65) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL8383277 | 0.77 | DDAH1 (0.51) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL31293729 | 0.77 | DDAH1 (0.51) | DDAH1ADRA2CALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4738504 | 0.76 | SMN1; SMN2 (0.44) | DDAH1ADRA2CSMN1; SMN2RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | claimed |
| US-4010033-A | PHOTOCHROMIC SPIROPYRANE, NITROGEN-CONTAINING THIOETHER | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1977-03-01 | — | — | US | claimed |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | DE KOCK HERMAN A | 2007-05-31 | — | — | US | disclosed |
| EP-1670773-B1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARM LTD (IE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1670773-A1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030739-A1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-04-07 | — | — | WO | disclosed |
| EP-0885608-A1 | REMEDIES FOR BRAIN DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-4873346-A | BRONCHODILATORS, TREATMENT OF ASTHMA | THE UPJOHN COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | STS, MPST, SULT1E1 | DDAH1 532/4885ADRA2C 4519/4885ALDH1A1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.